微生态制剂在胃肠道疾病中的临床应用
|
摘要
微生态制剂(microbial ecological agents, MEA)是利用益生菌及其代谢产物而制成的一种药物制剂。MEA主要是通过补充有益的微生物来重建人体肠道内的菌群平衡,以治疗多种胃肠道疾病。现就近年来MEA在胃肠道中的作用机制,以及在防治炎症性肠病、与抗生素相关的腹泻、幽门螺杆菌感染和慢性肝病等疾病中的临床应用作一概述,为更好地开发和利用MEA治疗疾病奠定基础。
Microbial ecological agents(MEA) are pharmaceutical preparations made up of probiotics and their metabolites. MEA mainly reconstitutes the balance of the flora in the human intestine by supplementing beneficial microorganisms to treat various gastro-intestinal diseases. In recent years, MEA has been outlined in the digestive system and its clinical application in the prevention and treatment of inflammatory bowel disease, antibiotic-associated diarrhea, Helicobacter pylori infection and chronic liver disease, in order to better develop and utilize MEA. It is laying the foundation in treatment the related diseases.
Microbial ecological agents(MEA) are pharmaceutical preparations made up of probiotics and their metabolites. MEA mainly reconstitutes the balance of the flora in the human intestine by supplementing beneficial microorganisms to treat various gastro-intestinal diseases. In recent years, MEA has been outlined in the digestive system and its clinical application in the prevention and treatment of inflammatory bowel disease, antibiotic-associated diarrhea, Helicobacter pylori infection and chronic liver disease, in order to better develop and utilize MEA. It is laying the foundation in treatment the related diseases.
引文
[1] FEIZIZADEH S, SALEHIABARGOUEI A, AKBARI V, et al. Efficacy and safety of Saccharomyces boulardii for acute diarrhea[J]. Pediatrics, 2014, 134(1):e176-191 .
[2] 王威, 杨强. 微生态制剂及其临床应用和研究进展[J]. 临床消化病杂志, 2010, 22(1): 56-59.
[3] 李春慧, 万霞, 吴润. 微生态态制剂应用研究概况[J]. 动物医学进展, 2013,34(11): 114-118.
[4] 张素莹. 微生态制剂在治疗胃肠道疾病中的应用研究[J].临床医学研究与实践, 2016,1 (1): 35.
[5] 张连水, 张慧霞, 孟会贤,等.微生态制剂的研究现状及前景[J]. 河北渔业, 2016(2): 56-59.
[6] 李小颖, 东玲. 肠道微生态及微生态制剂在治疗胃肠道疾病中的应用[J].西北药学杂志, 2009,24(2): 157-159.
[7] 曹乐民, 周云帆, 韩二芳. 微生态制剂的应用研究进展[J]. 河南农业, 2013 (4): 47-48.
[8] RUSSO F, INSALATA M, ORLANDO A. Probiotics against neoplastic transformation of gastric mucosa: Effects on cell proliferation and polyamine metabolism[J]. World J Gastroenterol, 2014, 20(37):13258-13272.
[9] FERNANDEZ J, EDONDO-BLANCO S, GUTIERREZ-DEL-RIO I, et al. Colon microbiota fermentation of dietary prebiotics towards short-chain fatty acids and their roles as anti-inflammatory and antitumour agents: A review[J]. J Funct Foods, 2016, 25: 511-522.
[10] SAMPSONT R, EBELIUS J W, THRON T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of parkinson’s disease[J]. Cell, 2016, 167(6): 1469-1480.
[11] SCHIRMER M, SMEEKENS S P, VLAMAKIS H, et al. Linking the human gut microbiome to inflammatory cytokine production capacity[J]. Cell, 2016, 167(4): 1125-1136.
[12] CHU H, KHOSRAVI A, KUSUMAWARDHANI I P, et al. Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease[J]. Science, 2016, 352(6289): 1116-1120.
[13] MCKENNEY P T, PAMER E G. From hype to hope: the gut microbiota in enteric infectious disease[J]. Cell, 2015, 163(6): 1326-1332.
[14] AMBALAM P, RAMAN M, PURAMA R K, et al. Probiotics, prebiotics and colorectal cancer prevention[J]. Best Pract Res Clin Gastroenterol, 2016, 30(1): 119-131.
[15] LIU D, JIANG X Y, ZHOU L S, et al. Effects of Probiotics on Intestinal Mucosa Barrier in Patients With Colorectal Cancer after Operation: Meta-Analysis of Randomized Controlled Trials[J]. Medicine, 2016, 95(15):e3342-3346.
[16] KANAI T, MIKAMI Y, HAYASHI A, et al. A breakthrough in probiotics: Clostridium butyricum regulates gut homeostasis and anti-inflammatory response in inflammatory bowel disease[J]. J Gastroenterol, 2015, 10(9): 928-939.
[17] SRINIVASJOIS R, RAO S. Prebiotic supplementation in preterm neonates: updated systematic review and meta-analysis of randomised controlled trials[J]. Clin Nutr, 2013, 32(6): 958-965.
[18] SHADNOUSH M, HOSSEINI R S, KHALILNEZHAD A, et al. Effects of Probiotics on Gut Microbiota in Patients with Inflammatory Bowel Disease: A Double-blind, Placebo-controlled Clinical Trial[J]. Korean J Gastroenterol, 2015, 65(4): 215-221.
[19] KONIECZNA P, AKDIS C A, QUIGLEY E M M, et al. Portrait of an immunoregulatory Bifidobacterium[J]. Gut Microbes, 2012, 3(3): 261-266.
[20] PEUKER K, MUFF S, WANG J, et al. Epithelial calcineurin controls microbiota-dependent intestinal tumor development[J]. Nat Med, 2016, 22(5): 506-515.
[21] 贺鸿杰. 联合益生菌的三联疗法与序贯疗法对幽门螺旋杆菌根治疗效比较[J]. 中国医药导刊, 2015, 17(4): 358-360.
[22] 杜三军, 温杰, 沈金库. 微生态制剂在幽门螺杆菌感染性胃病的治疗效果观察[J]. 中国预防医学杂志, 2016, 17(6): 461-463.
[23] ZHAO Y, F GUO X J, ZHANG Z S. Epidemiology of functional diarrhea and comparison with diarrhea-predominant irritable bowel syndrome: a population-based survey in China[J]. PLoS One, 2012, 7(8): e43749-43753.
[24] 郑跃杰, 黄志华, 刘作义. 微生态制剂儿科应用专家共识[J]. 中国实用儿科杂志, 2011, 26(1): 20-24.
[25] 黄灿, 程晟, 沈素. 微生态制剂及其临床应用研究进展[J]. 中国医院用药评价与分析, 2015,15(4): 440-442.
[26] WANG H, LEE I S, BRAUN C, et al. Effect of probiotics on central nervous system functions in animals and humans - a systematic review[J]. J Neurogastroenterol Motil, 2016,22(4): 589-605.
[27] KELLY J R, BORRE Y , O' Brien C, et al. Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat[J]. J Psychiatr Res, 2016, 82:109-118.
[28] CHEN C H, LIN C L, KAO C H, et al. Irritable bowel syndrome increases the risk of epilepsy: a population-based study[J]. Medicine, 2015, 94(36): e1497-1501.
[29] CONNORr D E, NIXON M, NANDA A, et al. Vagal nerve stimulation for the treatment of medically refractory epilepsy: a review of the current literature[J]. Neurosurgical Focus, 2012, 32(3): e12-16.
[30] KSHIRSAGAR V Y, NAGARSENKAR S, AHMED M, et al. Abdominal epilepsy in chronic recurrent abdominal pain[J]. J Pediatr Neurosci, 2012, 7(3): 163-166.
[31] NIKIFOROVA A S. Stress-induced gastrointestinal motility is responsible for epileptic susceptibility[J]. Med Hypotheses, 2014, 82(4): 442-451.
[32] XUE L, HE J , GAO N , et al, Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia[J]. Sci Rep, 2017, 7: 45176-45190.
[33] PUTTGNANI L, ALISI A, NOBILI V, et al. Pediatric NAFLD: the Future role of Patient-Tailored Probiotics Therapy[J]. J Pediatric Gastroenterol Nutr, 2016, 63(Suppl 1): S6-8.
[34] SAAB S, SURAWEERA D, AU J, et al. Probiotics are helpful in hepatic encephalopathy: a meta‐analysis of randomized trials[J]. Liver Int, 2016, 36(7): 986-993.
[35] YU T, ZHENG Y P, TAN J C, et al. Effects of Prebiotics and Synbiotics on Functional Constipation[J]. Am J Med Sci, 2016, 353(3):282-292.
[36] BARICHELLA M, PACCHETTI C, BOLLIRI C, et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT[J]. Neurology, 2016, 87(12):1274-1280.
[2] 王威, 杨强. 微生态制剂及其临床应用和研究进展[J]. 临床消化病杂志, 2010, 22(1): 56-59.
[3] 李春慧, 万霞, 吴润. 微生态态制剂应用研究概况[J]. 动物医学进展, 2013,34(11): 114-118.
[4] 张素莹. 微生态制剂在治疗胃肠道疾病中的应用研究[J].临床医学研究与实践, 2016,1 (1): 35.
[5] 张连水, 张慧霞, 孟会贤,等.微生态制剂的研究现状及前景[J]. 河北渔业, 2016(2): 56-59.
[6] 李小颖, 东玲. 肠道微生态及微生态制剂在治疗胃肠道疾病中的应用[J].西北药学杂志, 2009,24(2): 157-159.
[7] 曹乐民, 周云帆, 韩二芳. 微生态制剂的应用研究进展[J]. 河南农业, 2013 (4): 47-48.
[8] RUSSO F, INSALATA M, ORLANDO A. Probiotics against neoplastic transformation of gastric mucosa: Effects on cell proliferation and polyamine metabolism[J]. World J Gastroenterol, 2014, 20(37):13258-13272.
[9] FERNANDEZ J, EDONDO-BLANCO S, GUTIERREZ-DEL-RIO I, et al. Colon microbiota fermentation of dietary prebiotics towards short-chain fatty acids and their roles as anti-inflammatory and antitumour agents: A review[J]. J Funct Foods, 2016, 25: 511-522.
[10] SAMPSONT R, EBELIUS J W, THRON T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of parkinson’s disease[J]. Cell, 2016, 167(6): 1469-1480.
[11] SCHIRMER M, SMEEKENS S P, VLAMAKIS H, et al. Linking the human gut microbiome to inflammatory cytokine production capacity[J]. Cell, 2016, 167(4): 1125-1136.
[12] CHU H, KHOSRAVI A, KUSUMAWARDHANI I P, et al. Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease[J]. Science, 2016, 352(6289): 1116-1120.
[13] MCKENNEY P T, PAMER E G. From hype to hope: the gut microbiota in enteric infectious disease[J]. Cell, 2015, 163(6): 1326-1332.
[14] AMBALAM P, RAMAN M, PURAMA R K, et al. Probiotics, prebiotics and colorectal cancer prevention[J]. Best Pract Res Clin Gastroenterol, 2016, 30(1): 119-131.
[15] LIU D, JIANG X Y, ZHOU L S, et al. Effects of Probiotics on Intestinal Mucosa Barrier in Patients With Colorectal Cancer after Operation: Meta-Analysis of Randomized Controlled Trials[J]. Medicine, 2016, 95(15):e3342-3346.
[16] KANAI T, MIKAMI Y, HAYASHI A, et al. A breakthrough in probiotics: Clostridium butyricum regulates gut homeostasis and anti-inflammatory response in inflammatory bowel disease[J]. J Gastroenterol, 2015, 10(9): 928-939.
[17] SRINIVASJOIS R, RAO S. Prebiotic supplementation in preterm neonates: updated systematic review and meta-analysis of randomised controlled trials[J]. Clin Nutr, 2013, 32(6): 958-965.
[18] SHADNOUSH M, HOSSEINI R S, KHALILNEZHAD A, et al. Effects of Probiotics on Gut Microbiota in Patients with Inflammatory Bowel Disease: A Double-blind, Placebo-controlled Clinical Trial[J]. Korean J Gastroenterol, 2015, 65(4): 215-221.
[19] KONIECZNA P, AKDIS C A, QUIGLEY E M M, et al. Portrait of an immunoregulatory Bifidobacterium[J]. Gut Microbes, 2012, 3(3): 261-266.
[20] PEUKER K, MUFF S, WANG J, et al. Epithelial calcineurin controls microbiota-dependent intestinal tumor development[J]. Nat Med, 2016, 22(5): 506-515.
[21] 贺鸿杰. 联合益生菌的三联疗法与序贯疗法对幽门螺旋杆菌根治疗效比较[J]. 中国医药导刊, 2015, 17(4): 358-360.
[22] 杜三军, 温杰, 沈金库. 微生态制剂在幽门螺杆菌感染性胃病的治疗效果观察[J]. 中国预防医学杂志, 2016, 17(6): 461-463.
[23] ZHAO Y, F GUO X J, ZHANG Z S. Epidemiology of functional diarrhea and comparison with diarrhea-predominant irritable bowel syndrome: a population-based survey in China[J]. PLoS One, 2012, 7(8): e43749-43753.
[24] 郑跃杰, 黄志华, 刘作义. 微生态制剂儿科应用专家共识[J]. 中国实用儿科杂志, 2011, 26(1): 20-24.
[25] 黄灿, 程晟, 沈素. 微生态制剂及其临床应用研究进展[J]. 中国医院用药评价与分析, 2015,15(4): 440-442.
[26] WANG H, LEE I S, BRAUN C, et al. Effect of probiotics on central nervous system functions in animals and humans - a systematic review[J]. J Neurogastroenterol Motil, 2016,22(4): 589-605.
[27] KELLY J R, BORRE Y , O' Brien C, et al. Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat[J]. J Psychiatr Res, 2016, 82:109-118.
[28] CHEN C H, LIN C L, KAO C H, et al. Irritable bowel syndrome increases the risk of epilepsy: a population-based study[J]. Medicine, 2015, 94(36): e1497-1501.
[29] CONNORr D E, NIXON M, NANDA A, et al. Vagal nerve stimulation for the treatment of medically refractory epilepsy: a review of the current literature[J]. Neurosurgical Focus, 2012, 32(3): e12-16.
[30] KSHIRSAGAR V Y, NAGARSENKAR S, AHMED M, et al. Abdominal epilepsy in chronic recurrent abdominal pain[J]. J Pediatr Neurosci, 2012, 7(3): 163-166.
[31] NIKIFOROVA A S. Stress-induced gastrointestinal motility is responsible for epileptic susceptibility[J]. Med Hypotheses, 2014, 82(4): 442-451.
[32] XUE L, HE J , GAO N , et al, Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia[J]. Sci Rep, 2017, 7: 45176-45190.
[33] PUTTGNANI L, ALISI A, NOBILI V, et al. Pediatric NAFLD: the Future role of Patient-Tailored Probiotics Therapy[J]. J Pediatric Gastroenterol Nutr, 2016, 63(Suppl 1): S6-8.
[34] SAAB S, SURAWEERA D, AU J, et al. Probiotics are helpful in hepatic encephalopathy: a meta‐analysis of randomized trials[J]. Liver Int, 2016, 36(7): 986-993.
[35] YU T, ZHENG Y P, TAN J C, et al. Effects of Prebiotics and Synbiotics on Functional Constipation[J]. Am J Med Sci, 2016, 353(3):282-292.
[36] BARICHELLA M, PACCHETTI C, BOLLIRI C, et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT[J]. Neurology, 2016, 87(12):1274-1280.